Caris’ Precision Oncology Alliance Welcomes The Georgia Cancer Center at Augusta University | Texas News

IRVING, Texas, Nov. 11, 2021 /PRNewswire/ — Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced that Augusta’s Georgia Cancer Center University has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers around the world working together to advance precision oncology and biomarker-driven research. POA members collaborate to establish and optimize molecular testing standards of care through innovative research focused on predictive and prognostic markers that improve clinical outcomes for cancer patients.

The Georgia Cancer Center has a long history of providing clinical trials, including therapies developed in its own labs, for both adults and children with all types of cancer. Its relationship with the National Cancer Institute’s (NCI) National Oncology Research Programs began in 1994 with a predecessor, the Minority-Based Community Clinical Oncology Program, or MBCCOP. Today, the Georgia Cancer Center still directs the state’s only minority-based research program through NCI’s NCORP.

“We are excited to partner with other leading institutions focused on research and innovation through Caris’ Precision Oncology Alliance,” said Jorge E. Cortes, MD, director of the Georgia Cancer Center. “We are convinced that through clinical and translational research, we not only provide the best patient care, but also lead to necessary improvements in cancer diagnosis, prevention and treatment, now and in the future.”

The Georgia Cancer Center is on track to achieve National Cancer Institute nomination through the NCI Cancer Center Support Grant program — seeking the second institution in the state to do so. An NCI-designated cancer center is by definition a leader in nationally recognized cancer research, including clinical trials.

“The Georgia Cancer Center’s multidisciplinary approach to cancer care allows their physicians and researchers to focus on advancing innovation to improve outcomes for patients,” said Chadi Nabhan, MD, MBA, FACP, president of the Caris Precision Oncology Alliance. “The POA is excited to partner with partners such as the Georgia Cancer Center who support eliminating the threat of cancer by providing access to quality, research-based cancer care to everyone in their community. The clinical research talent that the Georgia Cancer Center compliments the POA’s strategic vision and mission statements and aims to enhance ongoing investigative capabilities.”

“The Georgia Cancer Center at Augusta University provides the most advanced cancer care in the region,” said Brian J. Brille, vice president of Caris Life Sciences. “Their team of top oncology doctors and researchers can support patients and their families with the latest advanced treatment options in precision medicine, and the POA welcomes their expertise in the field.”

Serving a dozen counties in Georgia, the Georgia Cancer Center provides comprehensive care for children and adults using a patient-first model, which emphasizes the best available treatments and a wide variety of support services, including integrative medicine. It also features multidisciplinary tumor boards, dedicated clinical trial research units, nurse navigators, on-site fusion, on-campus oncology, and blood and bone marrow transplantation, as well as surgical and medical oncology with the largest team of cancer specialists in the region.

The Caris Precision Oncology Alliance includes 55 cancer centers and academic institutions. These institutions will have early access to the comprehensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, Caris aims to empower this network to prioritize therapeutic options and determine which clinical trial opportunities can benefit their patients. come. POA members can also integrate with a growing portfolio of biomarker-led trials sponsored by biopharma. In addition, as a member of the POA, institutions have access to Caris CODEai™, the industry’s most comprehensive data solution with cancer treatment information and clinical outcomes for more than 275,000 patients with more than 1,000,000 data points per patient.

About Caris Life Sciences

Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinical genomic database and cognitive computing necessary to understand the molecular complexity of disease. This information provides an unparalleled resource and the ideal path forward to conduct the fundamental, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.

With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. The latest development from Caris, currently available within the Precision Oncology Alliance, is a blood-based circulating nucleic acid sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing of blood) and serial monitoring. the most powerful liquid biopsy test ever developed.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver and Basel, Switzerland. Caris provides services in the US, Europe, Asia and other international markets. For more information, visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).

About the Georgia Cancer Center at Augusta University

The Georgia Cancer Center at Augusta University is committed to reducing the burden of cancer in Georgia and around the world through superior care, innovation and education. Through unprecedented expansion, the Georgia Cancer Center provides access to more premium clinical trials, world-renowned experts, and life-saving options. For more information, visit Augusta.edu/Cancer.

Caris Life Sciences Media contact:

Allison Kreutzjans

Nobleman

Caris@Edelman.com

314-550-1327

The Georgia Cancer Center at Augusta Univ Media Contact:

Chris Curry

Communication and Marketing Manager

chrcurry@augusta.edu

706-799-8841

View original content to download multimedia: https://www.prnewswire.com/news-releases/caris-precision-oncology-alliance-welcomes-the-georgia-cancer-center-at-augusta-university-301421959.html

SOURCE Caris Life Sciences

Comments are closed.